PUBLISHER: IMARC | PRODUCT CODE: 1722757
PUBLISHER: IMARC | PRODUCT CODE: 1722757
The global anesthesia CO2 absorbent market size reached USD 82.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 132.8 Million by 2033, exhibiting a growth rate (CAGR) of 5.38% during 2025-2033. The increasing number of surgeries across hospitals and clinics is raising the demand for reliable absorbents, which is stimulating the market.
Anesthesia CO2 absorbent is a specific segment within the anesthesia disposables, which is primarily used to absorb exhaled gases during anesthesia administration. Consisting of strong potassium hydroxide and sodium hydroxide bases that help obtain labile protons from anesthetic molecules to carbon monoxide (CO), these absorbent formulations are instrumental in minimizing anesthetic wastes. The CO2 absorber devices consisting of anesthesia absorbents are incorporated into the ventilatory apparatus of the anesthesia machine between the inspiratory and expiratory limbs of a circle circuit. They function by limiting the flow of fresh gas to closed-circuit conditions and allowing exhaled anesthetic agents to be rebreathed. However, the production of carbon monoxide (CO) can cause health hazards to patients. Certain CO2 absorbents do not contain potassium hydroxide, and sodium hydroxide and consequently do not produce carbon monoxide by reacting with inhaled agents.
The market is primarily driven by the rising incidences of chronic conditions, such as cardiac disorders, neurological conditions, respiratory diseases, and diabetes. Along with this, the growing geriatric population that is susceptible to developing medical conditions ultimately requiring surgical intervention is providing a significant boost to the market. Besides this, with the rising number of surgeries conducted across numerous healthcare settings, there has been a considerable rise in the demand for anesthesia disposables, thereby contributing to the product adoption across the globe. Various stringent government guidelines and safety parameters regarding the usage of anesthetic drugs and equipment across the healthcare sector are further propelling the product demand. In addition to this, the increasing investments in the research and development (R&D) activities for developing advanced CO2 absorbing formulations and the expanding healthcare expenditure are also providing an impetus to the market growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Armstrong Medical Ltd. (Eakin Healthcare Group Ltd), Atrasorb, Dragerwerk AG & Co. KGaA, General Electric Company, Intersurgical Ltd., Lowenstein Medical SE & Co. KG, Micropore Inc., Molecular Products Group plc (Filtration Group Corporation) and Smiths Medical Inc. (ICU Medical Inc.).